Cantor Fitzgerald Expects Stronger Earnings for Verastem

Verastem, Inc. (NASDAQ:VSTM) – Stock analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Verastem in a report issued on Thursday, October 16th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the biopharmaceutical company will post earnings per share of ($2.60) for the year, up from their previous estimate of ($2.72). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem’s FY2026 earnings at ($2.06) EPS.

Verastem (NASDAQ:VSTM) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.25. The business had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $6.01 million.

A number of other brokerages also recently commented on VSTM. Royal Bank Of Canada set a $13.00 price target on shares of Verastem and gave the stock an “outperform” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Verastem in a report on Wednesday, October 8th. Zacks Research upgraded shares of Verastem to a “hold” rating in a report on Tuesday, August 12th. Wall Street Zen upgraded shares of Verastem from a “sell” rating to a “hold” rating in a report on Sunday, September 21st. Finally, B. Riley upgraded shares of Verastem to a “strong-buy” rating in a report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Verastem currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.14.

Verastem Stock Performance

NASDAQ:VSTM opened at $7.99 on Monday. The company has a current ratio of 3.46, a quick ratio of 3.44 and a debt-to-equity ratio of 2.06. The firm has a 50-day moving average price of $9.04 and a two-hundred day moving average price of $7.07. Verastem has a twelve month low of $3.11 and a twelve month high of $11.24. The company has a market capitalization of $491.70 million, a P/E ratio of -2.44 and a beta of 0.89.

Institutional Investors Weigh In On Verastem

Hedge funds have recently modified their holdings of the stock. E Fund Management Co. Ltd. acquired a new stake in shares of Verastem in the second quarter worth approximately $49,000. Nebula Research & Development LLC acquired a new stake in shares of Verastem in the second quarter worth approximately $53,000. The Manufacturers Life Insurance Company boosted its position in shares of Verastem by 9.8% in the second quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 1,440 shares during the last quarter. Profund Advisors LLC acquired a new stake in shares of Verastem in the second quarter worth approximately $90,000. Finally, Los Angeles Capital Management LLC acquired a new position in Verastem during the second quarter valued at approximately $106,000. 88.37% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Paul A. Bunn sold 8,333 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $9.06, for a total value of $75,496.98. Following the sale, the director directly owned 8,333 shares of the company’s stock, valued at approximately $75,496.98. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 11,005 shares of company stock valued at $96,552 over the last 90 days. 2.10% of the stock is currently owned by company insiders.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.